Study with Us
graduate study at the department of oncology
The Department of Oncology employs multidisciplinary approaches from physics, biology, chemistry and mathematical modelling to investigate DNA biology and epigenetics, cell and environmental biology of tumour tissue, and both systemic and local immunological responses in cancer.
The department offers an established, world-leading, graduate training programme. Our degree courses focus on expanding scientific knowledge, with particular emphasis on therapies involving drug discovery or action and therapies used in combination with radiotherapy.
Please take a moment to review the different courses available in this department and to hear what our students think on our Student Experience page.
- DPhil in Oncology
- MSc by Research in Oncology
- MSc in Precision Cancer Medicine
- MSc in Experimental and Translational Therapeutics
- MSc in Radiation Biology - not yet open for applications. Please email the Graduate Studies Office to request a notification when this course is open
Contact us at the Graduate Studies Office if you have any questions that are not answered here.
Blog posts
Department News
The Department represented at the European Radiation Research Society annual conference
30 September 2022
Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.
Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene
29 September 2022
A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.
Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine
5 August 2022
A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.